These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 35855586)

  • 21. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
    Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An economic analysis of conservative management versus active treatment for men with localized prostate cancer.
    Perlroth DJ; Bhattacharya J; Goldman DP; Garber AM
    J Natl Cancer Inst Monogr; 2012 Dec; 2012(45):250-7. PubMed ID: 23271781
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent trends in the initial therapy for newly diagnosed prostate cancer in Japan.
    Onozawa M; Hinotsu S; Tsukamoto T; Oya M; Ogawa O; Kitamura T; Suzuki K; Naito S; Namiki M; Nishimura K; Hirao Y; Akaza H
    Jpn J Clin Oncol; 2014 Oct; 44(10):969-81. PubMed ID: 25098707
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pathological upgrading in prostate cancer patients eligible for active surveillance: Does prostate-specific antigen density matter?
    Jin BS; Kang SH; Kim DY; Oh HG; Kim CI; Moon GH; Kwon TG; Park JS
    Korean J Urol; 2015 Sep; 56(9):624-9. PubMed ID: 26366274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study.
    Tohi Y; Kato T; Matsumoto R; Shinohara N; Shiga K; Yokomizo A; Nakamura M; Kume H; Mitsuzuka K; Sasaki H; Egawa S; Matsumura M; Hashine K; Inokuchi J; Eto M; Baba H; Ichikawa T; Kinoshita H; Matsuda T; Kakehi Y; Sugimoto M
    Int J Clin Oncol; 2020 Dec; 25(12):2107-2114. PubMed ID: 32770439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Feasibility for active surveillance in biopsy Gleason 3 + 4 prostate cancer: an Australian radical prostatectomy cohort.
    Wong LM; Tang V; Peters J; Costello A; Corcoran N
    BJU Int; 2016 Apr; 117 Suppl 4():82-7. PubMed ID: 27094971
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of predictors of unfavorable pathological features in men eligible for active surveillance using radical prostatectomy specimens: a multi-institutional study.
    Mizuno K; Inoue T; Kinoshita H; Yano T; Kawanishi H; Kanda H; Terada N; Kobayashi T; Kamba T; Mikami Y; Shiraishi T; Uemura Y; Imai Y; Honjo G; Shirase T; Okumura K; Kawakita M; Ogura K; Sugimura Y; Matsuda T; Ogawa O
    Jpn J Clin Oncol; 2016 Dec; 46(12):1156-1161. PubMed ID: 27744325
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter analysis of pathological outcomes of patients eligible for active surveillance according to PRIAS criteria.
    Grasso AA; Cozzi G; DE Lorenzis E; Ceruti C; Crivellaro S; Falsaperla M; Minervini A; Masieri L; Porreca A; Zaramella S; Rocco B
    Minerva Urol Nefrol; 2016 Jun; 68(3):237-41. PubMed ID: 25732225
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Indications for intervention during active surveillance of prostate cancer: a comparison of the Johns Hopkins and Prostate Cancer Research International Active Surveillance (PRIAS) protocols.
    Kates M; Tosoian JJ; Trock BJ; Feng Z; Carter HB; Partin AW
    BJU Int; 2015 Feb; 115(2):216-22. PubMed ID: 24904995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients.
    Çamur E; Coşkun A; Kavukoğlu Ӧ; Can U; Kara Ö; Develi Çamur A; Sarıca K; Narter KF
    Arch Ital Urol Androl; 2019 Jul; 91(2):. PubMed ID: 31266273
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Observation versus initial treatment for men with localized, low-risk prostate cancer: a cost-effectiveness analysis.
    Hayes JH; Ollendorf DA; Pearson SD; Barry MJ; Kantoff PW; Lee PA; McMahon PM
    Ann Intern Med; 2013 Jun; 158(12):853-60. PubMed ID: 23778902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Compliance Rates with the Prostate Cancer Research International Active Surveillance (PRIAS) Protocol and Disease Reclassification in Noncompliers.
    Bokhorst LP; Alberts AR; Rannikko A; Valdagni R; Pickles T; Kakehi Y; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Nov; 68(5):814-21. PubMed ID: 26138043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-Term Outcomes after Deferred Radical Prostatectomy in Men Initially Treated with Active Surveillance.
    Godtman RA; Schafferer M; Pihl CG; Stranne J; Hugosson J
    J Urol; 2018 Oct; 200(4):779-785. PubMed ID: 29730198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The cost-effectiveness of active surveillance compared to watchful waiting and radical prostatectomy for low risk localised prostate cancer.
    Lao C; Edlin R; Rouse P; Brown C; Holmes M; Gilling P; Lawrenson R
    BMC Cancer; 2017 Aug; 17(1):529. PubMed ID: 28789623
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes.
    Akaza H; Hinotsu S; Cooperberg MR; Chung BH; Youl Lee J; Umbas R; Tsukamoto T; Namiki M; Carroll P
    Jpn J Clin Oncol; 2013 Jul; 43(7):756-66. PubMed ID: 23723314
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biopsy features associated with prostate cancer progression in active surveillance patients: comparison of three statistical models.
    Iremashvili V; Manoharan M; Rosenberg DL; Soloway MS
    BJU Int; 2013 Apr; 111(4):574-9. PubMed ID: 22564446
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radical prostatectomy for low-risk prostate cancer following initial active surveillance: results from a prospective observational study.
    Bul M; Zhu X; Rannikko A; Staerman F; Valdagni R; Pickles T; Bangma CH; Roobol MJ
    Eur Urol; 2012 Aug; 62(2):195-200. PubMed ID: 22342775
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.